Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acne Vulgaris | 65 | 2024 | 351 | 31.470 |
Why?
|
Dermatologic Agents | 27 | 2024 | 312 | 11.910 |
Why?
|
Isotretinoin | 19 | 2024 | 134 | 8.410 |
Why?
|
Dermatology | 40 | 2023 | 904 | 6.770 |
Why?
|
Spironolactone | 15 | 2024 | 412 | 6.070 |
Why?
|
Granuloma Annulare | 8 | 2024 | 28 | 5.080 |
Why?
|
Psoriasis | 15 | 2024 | 927 | 5.030 |
Why?
|
Skin Diseases | 20 | 2023 | 1084 | 4.360 |
Why?
|
Benzoyl Peroxide | 5 | 2024 | 22 | 3.890 |
Why?
|
Anti-Bacterial Agents | 23 | 2024 | 7458 | 3.370 |
Why?
|
Rosacea | 3 | 2024 | 60 | 2.550 |
Why?
|
Drug Utilization | 6 | 2020 | 1191 | 2.210 |
Why?
|
Dermatitis, Atopic | 6 | 2024 | 733 | 2.160 |
Why?
|
Tetracyclines | 6 | 2024 | 64 | 2.030 |
Why?
|
Arthritis, Psoriatic | 3 | 2022 | 217 | 1.860 |
Why?
|
Benzene | 2 | 2024 | 106 | 1.790 |
Why?
|
Drug Prescriptions | 9 | 2024 | 1673 | 1.720 |
Why?
|
Antibiotic Prophylaxis | 5 | 2021 | 640 | 1.670 |
Why?
|
Quality of Life | 15 | 2024 | 13499 | 1.620 |
Why?
|
Calcitonin Gene-Related Peptide | 2 | 2024 | 328 | 1.510 |
Why?
|
Tetracycline | 3 | 2024 | 216 | 1.440 |
Why?
|
Retinoids | 6 | 2024 | 99 | 1.390 |
Why?
|
Mohs Surgery | 4 | 2021 | 217 | 1.310 |
Why?
|
Off-Label Use | 3 | 2019 | 185 | 1.270 |
Why?
|
Administration, Oral | 13 | 2024 | 4043 | 1.210 |
Why?
|
Contraception | 3 | 2020 | 362 | 1.200 |
Why?
|
Administration, Topical | 9 | 2024 | 703 | 1.180 |
Why?
|
Propionates | 4 | 2024 | 180 | 1.150 |
Why?
|
Severity of Illness Index | 14 | 2024 | 15939 | 1.150 |
Why?
|
Humans | 164 | 2024 | 768298 | 1.120 |
Why?
|
Contraceptives, Oral, Combined | 3 | 2024 | 117 | 1.040 |
Why?
|
Telemedicine | 7 | 2022 | 3107 | 0.950 |
Why?
|
Flushing | 1 | 2024 | 52 | 0.920 |
Why?
|
Prurigo | 1 | 2024 | 26 | 0.900 |
Why?
|
Medicare Part D | 2 | 2019 | 358 | 0.900 |
Why?
|
Salicylic Acid | 1 | 2024 | 62 | 0.900 |
Why?
|
Penicillanic Acid | 1 | 2024 | 41 | 0.890 |
Why?
|
Drug Costs | 5 | 2020 | 1196 | 0.890 |
Why?
|
Hidradenitis Suppurativa | 3 | 2023 | 176 | 0.890 |
Why?
|
Dicarboxylic Acids | 1 | 2024 | 75 | 0.880 |
Why?
|
Nonprescription Drugs | 1 | 2024 | 119 | 0.860 |
Why?
|
Dreams | 1 | 2024 | 146 | 0.840 |
Why?
|
Erythema | 1 | 2024 | 261 | 0.830 |
Why?
|
Pseudotumor Cerebri | 1 | 2024 | 107 | 0.820 |
Why?
|
Dietary Supplements | 3 | 2024 | 3443 | 0.820 |
Why?
|
Condylomata Acuminata | 1 | 2022 | 79 | 0.790 |
Why?
|
Eczema | 2 | 2023 | 245 | 0.780 |
Why?
|
Cosmetics | 1 | 2023 | 102 | 0.770 |
Why?
|
Doxycycline | 1 | 2024 | 347 | 0.770 |
Why?
|
Alopecia Areata | 1 | 2024 | 130 | 0.760 |
Why?
|
Research Design | 3 | 2023 | 6209 | 0.760 |
Why?
|
Cross-Sectional Studies | 20 | 2024 | 26373 | 0.750 |
Why?
|
Reimbursement Mechanisms | 2 | 2017 | 677 | 0.750 |
Why?
|
Office Management | 1 | 2021 | 13 | 0.750 |
Why?
|
Patient Satisfaction | 3 | 2024 | 3485 | 0.730 |
Why?
|
United States | 39 | 2024 | 73144 | 0.720 |
Why?
|
Hematologic Neoplasms | 2 | 2023 | 1906 | 0.710 |
Why?
|
Publications | 2 | 2019 | 196 | 0.710 |
Why?
|
Cortodoxone | 4 | 2024 | 18 | 0.710 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2021 | 187 | 0.700 |
Why?
|
Abnormalities, Drug-Induced | 2 | 2020 | 340 | 0.690 |
Why?
|
Onychomycosis | 1 | 2020 | 50 | 0.690 |
Why?
|
Adult | 52 | 2024 | 223622 | 0.690 |
Why?
|
Probiotics | 1 | 2023 | 383 | 0.670 |
Why?
|
Menstruation Disturbances | 1 | 2021 | 143 | 0.660 |
Why?
|
Biological Factors | 1 | 2020 | 158 | 0.660 |
Why?
|
Surgical Wound Infection | 5 | 2024 | 1544 | 0.660 |
Why?
|
Drug Resistance, Microbial | 2 | 2020 | 830 | 0.650 |
Why?
|
Teratogens | 1 | 2020 | 117 | 0.650 |
Why?
|
Young Adult | 27 | 2024 | 60048 | 0.640 |
Why?
|
Climate Change | 2 | 2023 | 508 | 0.640 |
Why?
|
Hyperlipidemias | 2 | 2021 | 773 | 0.640 |
Why?
|
Female | 67 | 2024 | 397050 | 0.630 |
Why?
|
Authorship | 1 | 2022 | 289 | 0.630 |
Why?
|
Office Visits | 2 | 2020 | 596 | 0.630 |
Why?
|
Diet, Protein-Restricted | 1 | 2018 | 73 | 0.610 |
Why?
|
Health Services Accessibility | 10 | 2024 | 5511 | 0.610 |
Why?
|
Fibromyalgia | 1 | 2023 | 406 | 0.600 |
Why?
|
Cicatrix | 1 | 2024 | 799 | 0.580 |
Why?
|
Relative Value Scales | 1 | 2017 | 86 | 0.580 |
Why?
|
Adolescent | 27 | 2024 | 89182 | 0.570 |
Why?
|
Social Stigma | 1 | 2024 | 785 | 0.560 |
Why?
|
Cohort Studies | 15 | 2024 | 41791 | 0.550 |
Why?
|
Practice Guidelines as Topic | 4 | 2024 | 7453 | 0.550 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2023 | 716 | 0.550 |
Why?
|
Inflammatory Bowel Diseases | 2 | 2023 | 2442 | 0.550 |
Why?
|
Nutrition Surveys | 1 | 2024 | 1736 | 0.550 |
Why?
|
Potassium | 1 | 2021 | 1319 | 0.540 |
Why?
|
Male | 54 | 2024 | 364870 | 0.520 |
Why?
|
Retrospective Studies | 26 | 2024 | 81768 | 0.520 |
Why?
|
Laser Therapy | 2 | 2024 | 1105 | 0.520 |
Why?
|
Autoimmune Diseases | 3 | 2024 | 2257 | 0.510 |
Why?
|
Comparative Effectiveness Research | 1 | 2021 | 712 | 0.510 |
Why?
|
Medicaid | 3 | 2024 | 2842 | 0.500 |
Why?
|
Physician Incentive Plans | 1 | 2017 | 165 | 0.500 |
Why?
|
Drug Substitution | 1 | 2018 | 291 | 0.500 |
Why?
|
General Practice | 1 | 2016 | 101 | 0.490 |
Why?
|
Patient Care | 1 | 2021 | 629 | 0.490 |
Why?
|
Psychometrics | 2 | 2024 | 3069 | 0.480 |
Why?
|
Skin Neoplasms | 5 | 2021 | 5857 | 0.480 |
Why?
|
Publishing | 1 | 2022 | 836 | 0.470 |
Why?
|
Skin | 6 | 2022 | 4499 | 0.470 |
Why?
|
Health Services | 1 | 2020 | 756 | 0.470 |
Why?
|
International Classification of Diseases | 1 | 2020 | 924 | 0.470 |
Why?
|
Minocycline | 3 | 2024 | 170 | 0.470 |
Why?
|
Drug Therapy, Combination | 5 | 2024 | 6319 | 0.460 |
Why?
|
Video Recording | 1 | 2019 | 974 | 0.460 |
Why?
|
Health Care Reform | 3 | 2017 | 1262 | 0.430 |
Why?
|
Venous Thrombosis | 1 | 2023 | 1317 | 0.430 |
Why?
|
Drug Industry | 2 | 2020 | 793 | 0.430 |
Why?
|
Drugs, Generic | 2 | 2020 | 454 | 0.430 |
Why?
|
Treatment Outcome | 16 | 2024 | 65365 | 0.420 |
Why?
|
Patient Admission | 1 | 2020 | 1367 | 0.410 |
Why?
|
Reimbursement, Incentive | 2 | 2017 | 548 | 0.410 |
Why?
|
Triglycerides | 2 | 2022 | 2465 | 0.400 |
Why?
|
Drug Discovery | 1 | 2020 | 1067 | 0.400 |
Why?
|
Periodicals as Topic | 3 | 2020 | 1469 | 0.400 |
Why?
|
Commerce | 1 | 2017 | 612 | 0.390 |
Why?
|
Middle Aged | 30 | 2024 | 223463 | 0.390 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2023 | 4357 | 0.380 |
Why?
|
Databases, Factual | 6 | 2023 | 8072 | 0.360 |
Why?
|
Vaccines | 3 | 2024 | 842 | 0.360 |
Why?
|
Staphylococcal Infections | 1 | 2019 | 1398 | 0.350 |
Why?
|
Pain Measurement | 1 | 2021 | 3579 | 0.350 |
Why?
|
Migraine Disorders | 1 | 2023 | 1713 | 0.350 |
Why?
|
Time Factors | 10 | 2021 | 40267 | 0.340 |
Why?
|
Decision Support Techniques | 1 | 2020 | 2005 | 0.330 |
Why?
|
Venous Thromboembolism | 1 | 2023 | 1881 | 0.330 |
Why?
|
Pain | 2 | 2024 | 5102 | 0.330 |
Why?
|
Patient Education as Topic | 1 | 2019 | 2337 | 0.330 |
Why?
|
Pulmonary Embolism | 1 | 2023 | 2587 | 0.330 |
Why?
|
Forecasting | 5 | 2019 | 2948 | 0.320 |
Why?
|
Contraceptive Agents, Female | 2 | 2020 | 123 | 0.310 |
Why?
|
Administration, Cutaneous | 2 | 2024 | 716 | 0.300 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2024 | 3620 | 0.300 |
Why?
|
Incidence | 6 | 2023 | 21544 | 0.300 |
Why?
|
Child | 16 | 2024 | 80894 | 0.290 |
Why?
|
Multiple Sclerosis | 1 | 2023 | 3247 | 0.290 |
Why?
|
Reproducibility of Results | 6 | 2024 | 20224 | 0.290 |
Why?
|
Healthcare Disparities | 2 | 2020 | 3412 | 0.280 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2021 | 12239 | 0.280 |
Why?
|
Mass Screening | 2 | 2020 | 5451 | 0.280 |
Why?
|
Cost-Benefit Analysis | 4 | 2023 | 5538 | 0.280 |
Why?
|
Artificial Intelligence | 2 | 2020 | 2661 | 0.280 |
Why?
|
Triage | 1 | 2014 | 994 | 0.280 |
Why?
|
Early Detection of Cancer | 2 | 2020 | 3236 | 0.270 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2020 | 10377 | 0.270 |
Why?
|
Primary Health Care | 2 | 2020 | 4748 | 0.270 |
Why?
|
Air Pollution | 1 | 2020 | 2363 | 0.260 |
Why?
|
Medicare | 3 | 2021 | 6881 | 0.260 |
Why?
|
Physicians | 2 | 2021 | 4614 | 0.260 |
Why?
|
Evidence-Based Medicine | 4 | 2024 | 3707 | 0.260 |
Why?
|
Breast Neoplasms | 2 | 2024 | 21163 | 0.250 |
Why?
|
Injections, Intralesional | 2 | 2024 | 280 | 0.250 |
Why?
|
Referral and Consultation | 2 | 2018 | 3627 | 0.240 |
Why?
|
Biopsy | 5 | 2021 | 6808 | 0.240 |
Why?
|
Models, Theoretical | 1 | 2017 | 3579 | 0.240 |
Why?
|
Antifungal Agents | 2 | 2020 | 757 | 0.240 |
Why?
|
Depression | 2 | 2020 | 8241 | 0.210 |
Why?
|
Outpatients | 2 | 2021 | 1603 | 0.210 |
Why?
|
Pemphigus | 1 | 2024 | 107 | 0.210 |
Why?
|
Carbon Footprint | 1 | 2022 | 19 | 0.210 |
Why?
|
Melanosis | 1 | 2024 | 93 | 0.210 |
Why?
|
Adrenal Cortex Hormones | 2 | 2024 | 1890 | 0.200 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3118 | 0.200 |
Why?
|
Hyperpigmentation | 1 | 2024 | 116 | 0.200 |
Why?
|
Pemphigoid, Bullous | 1 | 2024 | 110 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3241 | 0.200 |
Why?
|
Gels | 1 | 2023 | 421 | 0.200 |
Why?
|
Diet | 1 | 2020 | 8097 | 0.200 |
Why?
|
Cost of Illness | 3 | 2021 | 1959 | 0.200 |
Why?
|
Hirsutism | 1 | 2022 | 68 | 0.200 |
Why?
|
Emergency Service, Hospital | 2 | 2023 | 7955 | 0.200 |
Why?
|
Stereotyping | 1 | 2024 | 242 | 0.190 |
Why?
|
Neoplasms | 2 | 2021 | 22389 | 0.190 |
Why?
|
Health Care Costs | 3 | 2022 | 3267 | 0.190 |
Why?
|
Coal Tar | 1 | 2020 | 17 | 0.180 |
Why?
|
Pandemics | 2 | 2022 | 8750 | 0.180 |
Why?
|
Africa | 1 | 2023 | 726 | 0.180 |
Why?
|
Hypertension | 1 | 2020 | 8615 | 0.180 |
Why?
|
Petrolatum | 1 | 2020 | 7 | 0.180 |
Why?
|
Sexual Abstinence | 1 | 2020 | 17 | 0.170 |
Why?
|
United States Food and Drug Administration | 2 | 2019 | 1672 | 0.170 |
Why?
|
Intrauterine Devices, Copper | 1 | 2020 | 31 | 0.170 |
Why?
|
Delphi Technique | 2 | 2022 | 888 | 0.170 |
Why?
|
Contraceptive Devices, Female | 1 | 2020 | 40 | 0.170 |
Why?
|
Aged | 16 | 2024 | 171544 | 0.170 |
Why?
|
Warts | 1 | 2020 | 66 | 0.170 |
Why?
|
Intrauterine Devices, Medicated | 1 | 2020 | 30 | 0.170 |
Why?
|
Prevalence | 3 | 2023 | 15868 | 0.170 |
Why?
|
Tablets | 1 | 2020 | 149 | 0.170 |
Why?
|
Emollients | 1 | 2020 | 42 | 0.170 |
Why?
|
Policy | 1 | 2024 | 514 | 0.170 |
Why?
|
Levonorgestrel | 1 | 2020 | 80 | 0.170 |
Why?
|
Cardiovascular Diseases | 2 | 2024 | 15652 | 0.170 |
Why?
|
Medication Adherence | 2 | 2024 | 2189 | 0.170 |
Why?
|
Patient Acceptance of Health Care | 3 | 2022 | 3230 | 0.170 |
Why?
|
Personal Satisfaction | 1 | 2024 | 647 | 0.160 |
Why?
|
Health Records, Personal | 1 | 2020 | 127 | 0.160 |
Why?
|
Prostatic Neoplasms | 1 | 2022 | 11220 | 0.160 |
Why?
|
Chronic Disease | 3 | 2024 | 9380 | 0.160 |
Why?
|
Search Engine | 1 | 2020 | 142 | 0.160 |
Why?
|
Prescriptions | 1 | 2021 | 388 | 0.160 |
Why?
|
Journal Impact Factor | 1 | 2020 | 156 | 0.160 |
Why?
|
Facial Dermatoses | 1 | 2019 | 87 | 0.160 |
Why?
|
Minnesota | 1 | 2019 | 338 | 0.150 |
Why?
|
Information Seeking Behavior | 1 | 2019 | 116 | 0.150 |
Why?
|
Nails | 1 | 2020 | 297 | 0.150 |
Why?
|
Professional Staff Committees | 1 | 2017 | 37 | 0.150 |
Why?
|
Poisson Distribution | 1 | 2019 | 509 | 0.150 |
Why?
|
Condoms | 1 | 2020 | 338 | 0.150 |
Why?
|
Gender Identity | 1 | 2023 | 770 | 0.150 |
Why?
|
Liver Function Tests | 1 | 2019 | 525 | 0.150 |
Why?
|
Tacrolimus | 1 | 2021 | 750 | 0.140 |
Why?
|
Health Policy | 2 | 2020 | 2698 | 0.140 |
Why?
|
Personnel Selection | 1 | 2019 | 201 | 0.140 |
Why?
|
Drug Combinations | 1 | 2023 | 2078 | 0.140 |
Why?
|
Risk Factors | 5 | 2024 | 74954 | 0.140 |
Why?
|
Epidemiologic Studies | 1 | 2020 | 678 | 0.140 |
Why?
|
Esthetics | 1 | 2018 | 330 | 0.140 |
Why?
|
Pruritus | 1 | 2020 | 380 | 0.140 |
Why?
|
Costs and Cost Analysis | 1 | 2022 | 1669 | 0.130 |
Why?
|
Health Care Surveys | 3 | 2021 | 2437 | 0.130 |
Why?
|
Pathology, Clinical | 1 | 2020 | 376 | 0.130 |
Why?
|
Efficiency | 1 | 2019 | 477 | 0.130 |
Why?
|
Decision Making | 3 | 2024 | 3953 | 0.130 |
Why?
|
Remote Consultation | 1 | 2018 | 242 | 0.130 |
Why?
|
Sex Factors | 2 | 2020 | 10656 | 0.130 |
Why?
|
Attitude of Health Personnel | 2 | 2021 | 3921 | 0.130 |
Why?
|
Phototherapy | 1 | 2018 | 367 | 0.120 |
Why?
|
Qualitative Research | 3 | 2021 | 3131 | 0.120 |
Why?
|
Vitamins | 1 | 2023 | 1638 | 0.120 |
Why?
|
Checklist | 1 | 2022 | 843 | 0.120 |
Why?
|
Drainage | 1 | 2021 | 1183 | 0.120 |
Why?
|
Propensity Score | 1 | 2023 | 1955 | 0.120 |
Why?
|
Microscopy | 1 | 2020 | 909 | 0.120 |
Why?
|
Alopecia | 1 | 2019 | 416 | 0.120 |
Why?
|
Australia | 1 | 2018 | 1265 | 0.120 |
Why?
|
Drug Monitoring | 1 | 2021 | 964 | 0.120 |
Why?
|
Analgesics, Opioid | 2 | 2021 | 3836 | 0.120 |
Why?
|
Carcinoma, Basal Cell | 1 | 2020 | 562 | 0.120 |
Why?
|
Tetrazoles | 1 | 2020 | 923 | 0.120 |
Why?
|
Cluster Analysis | 1 | 2021 | 2727 | 0.110 |
Why?
|
Immunologic Factors | 1 | 2023 | 1598 | 0.110 |
Why?
|
Patient Preference | 1 | 2021 | 947 | 0.110 |
Why?
|
Sexual Behavior | 1 | 2023 | 2200 | 0.110 |
Why?
|
Multicenter Studies as Topic | 1 | 2018 | 1727 | 0.110 |
Why?
|
Counseling | 1 | 2021 | 1553 | 0.110 |
Why?
|
Age Factors | 2 | 2020 | 18472 | 0.110 |
Why?
|
Models, Economic | 1 | 2017 | 718 | 0.110 |
Why?
|
Risk Assessment | 3 | 2019 | 24316 | 0.110 |
Why?
|
Physicians, Primary Care | 1 | 2020 | 623 | 0.110 |
Why?
|
Alcoholism | 1 | 2024 | 1981 | 0.100 |
Why?
|
Vulnerable Populations | 1 | 2018 | 718 | 0.100 |
Why?
|
Cholesterol | 1 | 2022 | 2912 | 0.100 |
Why?
|
Societies, Medical | 3 | 2021 | 3960 | 0.100 |
Why?
|
Recurrence | 1 | 2024 | 8501 | 0.100 |
Why?
|
Monitoring, Physiologic | 1 | 2019 | 1795 | 0.090 |
Why?
|
Physician's Role | 1 | 2018 | 926 | 0.090 |
Why?
|
Insurance, Health | 2 | 2020 | 2518 | 0.090 |
Why?
|
Consensus | 1 | 2020 | 3212 | 0.090 |
Why?
|
Health Surveys | 1 | 2021 | 4056 | 0.090 |
Why?
|
Prescription Drugs | 1 | 2018 | 634 | 0.090 |
Why?
|
Data Interpretation, Statistical | 1 | 2020 | 2708 | 0.090 |
Why?
|
Life Style | 1 | 2021 | 3930 | 0.080 |
Why?
|
Patient-Centered Care | 1 | 2020 | 1447 | 0.080 |
Why?
|
Pregnancy | 2 | 2022 | 30198 | 0.080 |
Why?
|
Ambulatory Care | 1 | 2020 | 2784 | 0.080 |
Why?
|
Core Binding Factor Alpha 3 Subunit | 1 | 2008 | 57 | 0.080 |
Why?
|
Physician-Patient Relations | 2 | 2020 | 3267 | 0.080 |
Why?
|
Pyridines | 1 | 2020 | 2889 | 0.080 |
Why?
|
Particulate Matter | 1 | 2020 | 2609 | 0.080 |
Why?
|
Data Collection | 1 | 2017 | 3324 | 0.070 |
Why?
|
Antiviral Agents | 1 | 2020 | 3064 | 0.070 |
Why?
|
Case-Control Studies | 2 | 2024 | 22292 | 0.070 |
Why?
|
Length of Stay | 1 | 2020 | 6516 | 0.070 |
Why?
|
Longitudinal Studies | 2 | 2020 | 14783 | 0.060 |
Why?
|
Hospital Mortality | 1 | 2020 | 5367 | 0.060 |
Why?
|
Double-Blind Method | 1 | 2020 | 12457 | 0.060 |
Why?
|
Students, Medical | 1 | 2019 | 1964 | 0.060 |
Why?
|
Guideline Adherence | 1 | 2016 | 2240 | 0.060 |
Why?
|
Proportional Hazards Models | 1 | 2020 | 12557 | 0.060 |
Why?
|
Prospective Studies | 4 | 2024 | 54921 | 0.060 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5375 | 0.060 |
Why?
|
Predictive Value of Tests | 1 | 2020 | 15455 | 0.060 |
Why?
|
Aged, 80 and over | 4 | 2021 | 59683 | 0.050 |
Why?
|
Phenotype | 1 | 2021 | 16716 | 0.050 |
Why?
|
Cost Savings | 2 | 2018 | 915 | 0.050 |
Why?
|
Needs Assessment | 2 | 2018 | 1142 | 0.050 |
Why?
|
Interviews as Topic | 2 | 2020 | 2740 | 0.050 |
Why?
|
Melanoma | 1 | 2020 | 5705 | 0.050 |
Why?
|
Quality of Health Care | 1 | 2016 | 4339 | 0.050 |
Why?
|
Vaccination | 2 | 2023 | 3431 | 0.050 |
Why?
|
Legislation, Pharmacy | 1 | 2020 | 3 | 0.040 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2024 | 794 | 0.040 |
Why?
|
Current Procedural Terminology | 1 | 2021 | 101 | 0.040 |
Why?
|
Immunocompetence | 1 | 2020 | 138 | 0.040 |
Why?
|
Economics, Pharmaceutical | 1 | 2020 | 88 | 0.040 |
Why?
|
Macrolides | 1 | 2020 | 205 | 0.040 |
Why?
|
Tretinoin | 1 | 2022 | 524 | 0.040 |
Why?
|
Photography | 1 | 2022 | 537 | 0.040 |
Why?
|
Prognosis | 1 | 2019 | 30020 | 0.040 |
Why?
|
Carbon Dioxide | 1 | 2022 | 1149 | 0.040 |
Why?
|
Fees, Pharmaceutical | 1 | 2018 | 66 | 0.040 |
Why?
|
Philadelphia | 1 | 2018 | 271 | 0.040 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2023 | 4047 | 0.040 |
Why?
|
Review Literature as Topic | 1 | 2019 | 353 | 0.040 |
Why?
|
Health Personnel | 2 | 2023 | 3381 | 0.030 |
Why?
|
Temperature | 1 | 2023 | 2234 | 0.030 |
Why?
|
Health Plan Implementation | 1 | 2020 | 338 | 0.030 |
Why?
|
Attitude | 1 | 2022 | 772 | 0.030 |
Why?
|
Travel | 1 | 2022 | 800 | 0.030 |
Why?
|
Patient Protection and Affordable Care Act | 2 | 2016 | 1189 | 0.030 |
Why?
|
Follow-Up Studies | 1 | 2018 | 39405 | 0.030 |
Why?
|
Bibliometrics | 1 | 2020 | 355 | 0.030 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2020 | 390 | 0.030 |
Why?
|
Patients | 1 | 2023 | 909 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 2019 | 13696 | 0.030 |
Why?
|
Cities | 1 | 2018 | 543 | 0.030 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2019 | 495 | 0.030 |
Why?
|
Meta-Analysis as Topic | 1 | 2020 | 1364 | 0.030 |
Why?
|
Minority Groups | 1 | 2022 | 1215 | 0.030 |
Why?
|
Steroids | 1 | 2020 | 936 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2020 | 863 | 0.030 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2024 | 2277 | 0.030 |
Why?
|
Rheumatology | 1 | 2020 | 619 | 0.030 |
Why?
|
History, 21st Century | 1 | 2020 | 1575 | 0.030 |
Why?
|
Hospitalization | 1 | 2014 | 10844 | 0.030 |
Why?
|
Androgen Antagonists | 1 | 2023 | 1421 | 0.030 |
Why?
|
Treatment Failure | 1 | 2020 | 2664 | 0.030 |
Why?
|
Observer Variation | 1 | 2020 | 2623 | 0.030 |
Why?
|
Models, Organizational | 1 | 2016 | 548 | 0.030 |
Why?
|
Drug Resistance, Bacterial | 1 | 2020 | 1063 | 0.030 |
Why?
|
Schools, Medical | 1 | 2019 | 881 | 0.030 |
Why?
|
Insurance Coverage | 1 | 2024 | 1946 | 0.030 |
Why?
|
History, 20th Century | 1 | 2020 | 2771 | 0.020 |
Why?
|
Ovarian Neoplasms | 1 | 2008 | 4908 | 0.020 |
Why?
|
Perception | 1 | 2018 | 1206 | 0.020 |
Why?
|
Fee-for-Service Plans | 1 | 2016 | 714 | 0.020 |
Why?
|
Drug Approval | 1 | 2018 | 818 | 0.020 |
Why?
|
Faculty, Medical | 1 | 2019 | 1218 | 0.020 |
Why?
|
Pilot Projects | 1 | 2024 | 8730 | 0.020 |
Why?
|
Linear Models | 1 | 2020 | 5878 | 0.020 |
Why?
|
Communicable Diseases | 1 | 2018 | 873 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2019 | 2783 | 0.020 |
Why?
|
Cell Growth Processes | 1 | 2008 | 381 | 0.020 |
Why?
|
Infant | 2 | 2020 | 36512 | 0.020 |
Why?
|
Child, Preschool | 2 | 2020 | 42654 | 0.020 |
Why?
|
Ovary | 1 | 2008 | 960 | 0.010 |
Why?
|
Cytoplasm | 1 | 2008 | 1500 | 0.010 |
Why?
|
Gene Silencing | 1 | 2008 | 1501 | 0.010 |
Why?
|
Up-Regulation | 1 | 2008 | 4137 | 0.010 |
Why?
|
RNA, Small Interfering | 1 | 2008 | 3436 | 0.010 |
Why?
|
Internship and Residency | 1 | 2019 | 5948 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2008 | 11117 | 0.010 |
Why?
|
Cell Line | 1 | 2008 | 15593 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2008 | 12801 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2008 | 8628 | 0.010 |
Why?
|